Amgen (AMGN) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amgen (AMGN) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 29.1% versus a gain of 6.2%. Over five years, AMGN leads with a +116.6% price change compared with +73.1% for NBIX. Amgen is the larger company by market cap ($235.64 billion vs $15.24 billion), about 15.5 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +10.0%).
On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.2x vs 17.3x for Amgen). Amgen pays a dividend yielding 2.28%, while Neurocrine Biosciences does not currently pay one. Amgen converts more of its revenue into profit, with a net margin of 21.0% versus 16.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | NBIX |
|---|---|---|
| Share price | $435.64 | $150.57 |
| Market cap | $235.64B | $15.24B |
| 1-day change | -0.15% | -3.84% |
| YTD return | +33.10% | +6.16% |
| 1-year return | +29.06% | +6.16% |
| 5-year return | +116.64% | +73.11% |
| P/E ratio (TTM) | 25.25 | 22.34 |
| Forward P/E | 17.34 | 12.24 |
| EPS (TTM) | $17.25 | $6.74 |
| Dividend yield | 2.28% | 0.00% |
| Annual dividend | $9.94 | $0.00 |
| Revenue (latest FY) | $36.75B | $2.86B |
| Revenue growth (YoY) | +9.95% | +21.45% |
| Net income (latest FY) | $7.71B | $478.60M |
| Gross margin | 67.25% | 98.18% |
| Operating margin | 24.71% | 21.64% |
| Net margin | 20.98% | 16.73% |
| 52-week high | $483.99 | $186.12 |
| 52-week low | $312.39 | $122.14 |
| Distance from 52-week high | -9.99% | -19.10% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -0.88% | +38.50% |
| Average volume | 2.82M | 1.34M |
| Shares outstanding | 540.91M | 101.22M |
| Employees | 31,500 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen is about 15.5 times larger than Neurocrine Biosciences by market value ($235.64B vs $15.24B).
- AMGN has outperformed NBIX by 22.9 percentage points over the past year.
- Amgen offers a meaningfully higher dividend yield (2.28% vs 0.00%).
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +9.95%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
AMGN vs NBIX FAQ
Which is bigger, Amgen or Neurocrine Biosciences?
Amgen (AMGN) is larger, with a market capitalization of $235.64B compared with $15.24B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, AMGN or NBIX?
AMGN returned +29.06% over the past 12 months, compared with +6.16% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or NBIX?
NBIX has the lower trailing P/E at 22.3, versus 25.3 for AMGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or Neurocrine Biosciences?
Amgen pays a dividend yielding 2.28%, while Neurocrine Biosciences does not currently pay a regular dividend.
Are Amgen and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.